Xenetic Biosciences filings document the regulatory record for a Nasdaq-listed biopharmaceutical company developing DNase-based immuno-oncology technologies. Its Form 8-K reports cover operating and financial results, material events, capital-structure disclosures, equity incentive activity and governance matters tied to the company’s common stock.
Proxy materials describe annual meeting proposals, director elections, shareholder voting mechanics and board-related governance. The filing record also captures disclosures related to the company’s DNase program, collaboration activity, compensation arrangements, quorum and proxy-solicitation matters, and other formal updates affecting corporate reporting and stockholder approvals.
Xenetic Biosciences (XBIO) announced an updated investor presentation for its pending share exchange transaction with Santersus AG. The proposed transaction is subject to Xenetic stockholder approval and is expected to close in Q4 2026. At closing, Santersus would become a wholly owned subsidiary and continue as the combined company’s operating business; the combined company is expected to trade on Nasdaq as SNTS. The presentation lists negotiated valuations of $21 million for Xenetic and $120 million for Santersus, with a total estimated transaction valuation of $141 million. The Xenetic valuation assumes $0 Net Cash and is subject to adjustment. It estimates Santersus shareholders would own approximately 85% and Xenetic stockholders approximately 15%, subject to adjustment, and illustrates approximately 14,552,566 new Xenetic shares issued at closing; actual issuance is determined by the Exchange Ratio.
The presentation also reports that a retrospective analysis of 10 NucleoCapture compassionate-use cases in SLE showed median SLEDAI-2K of 17.5 before and 8.0 after three treatments (p=0.009).
Xenetic Biosciences, Inc. (XBIO) is the subject of a Schedule 13G filing by MJL Manager LLC and Michael Liu reporting that they currently hold no beneficial ownership of the company’s common stock. The filing lists 0 shares beneficially owned, representing 0% of the outstanding common stock, with no sole or shared voting or dispositive power.
Xenetic Biosciences, Inc. (XBIO) entered into a Share Exchange Agreement to acquire all of the outstanding share capital of Swiss company Santersus AG in an all‑stock transaction, with Santersus becoming a wholly owned subsidiary. At closing, Santersus shareholders are expected to own approximately 85% and existing Xenetic stockholders about 15% of the combined company on a fully diluted, as‑converted basis, subject to net cash and other adjustments. The combined company is expected to be renamed Santersus Bio, Inc. and listed on the Nasdaq Capital Market under the symbol “SNTS”, with an eight‑member board (six designated by Santersus and two by Xenetic) and Santersus CEO James Ladtkow leading management. Closing is targeted for the fourth quarter of 2026 and is conditioned on Xenetic stockholder approval, effectiveness of a resale Form S‑1, Nasdaq listing approval for the new shares, and other customary conditions; Xenetic may owe a $500,000 termination fee and up to $300,000 in expense reimbursement in certain break scenarios.
Xenetic Biosciences, Inc. reported financial results for the quarter ended June 30, 2026 and highlighted progress on its proprietary DNase immuno-oncology platform. Royalty revenue for the quarter was approximately $0.7 million, up about 12% from approximately $0.6 million in the prior-year period, contributing to approximately $1.5 million in royalty revenue during the first six months of 2026.
Research and development expenses decreased to approximately $0.6 million, while general and administrative expenses rose to approximately $1.1 million, largely due to higher legal costs tied to an ongoing strategic review process. Net loss for the quarter was approximately $0.9 million. The company ended the second quarter with approximately $6.5 million in cash and cash equivalents, compared to approximately $7.9 million as of December 31, 2025, and continues to advance its DNase platform through preclinical, translational and collaborative research efforts.
Xenetic Biosciences, Inc., a pre-commercial biopharmaceutical company developing DNase-based immune-oncology therapies for difficult-to-treat solid tumors, reported Q2 2026 royalty revenue of $660,601, all from its PolyXen sublicense with Takeda. Six‑month 2026 revenue was $1,467,524, a 24.0% increase over the prior‑year period.
The company recorded a Q2 2026 net loss of $929,695 and a six‑month 2026 net loss of $1,386,077, compared with a loss of $1,591,844 in the first half of 2025. Operating expenses for the first half totaled $2,941,331, with research and development of $1,213,456 and general and administrative of $1,727,875, the latter rising mainly from legal costs tied to a strategic review.
As of June 30, 2026, Xenetic held $6,471,766 in cash, total assets of $6,967,998, current liabilities of $894,977 and working capital of approximately $5.8 million. Management believes existing resources will fund operations for at least twelve months, but additional long‑term capital will be required. All Series B preferred shares were converted into roughly 45,000 common shares, leaving no preferred outstanding and only about 800 warrants. The board is conducting a formal strategic review that may include a sale, asset sale or reverse merger, with no assurance any transaction will occur.
Xenetic Biosciences, Inc. Schedule 13G reports beneficial ownership by MJL Manager LLC and Michael Liu. MJL Manager LLC holds 93,565 shares (reported as 4.1% of the class) and Michael Liu holds 126,741 shares (5.5%), with shared voting and dispositive power reported.
The filing states Michael Liu is sole control person of MJL and both reporting persons disclaim beneficial ownership of each other’s shares except for their pecuniary interest; signatures are dated 05/29/2026.
Xenetic Biosciences, Inc. amendment reports that Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation beneficially own 137,440 shares of Common Stock, equal to 6.00% of the class. The filing notes certain funds managed by RTC have rights to dividends and sale proceeds.
Xenetic Biosciences reported first quarter 2026 results showing higher royalty revenue and a smaller loss while advancing its DNase oncology platform. Royalty revenue for the three months ended March 31, 2026 rose about 36% to approximately $0.8 million from about $0.6 million a year earlier, mainly from its sublicense with Takeda.
Research and development expenses fell to roughly $0.7 million and general and administrative expenses edged down to about $0.6 million, contributing to a reduced net loss of approximately $0.5 million versus about $0.9 million in 2025. The company ended the quarter with around $7.3 million in cash and continues to evaluate strategic alternatives while progressing translational research, investigator-initiated studies and manufacturing readiness for its DNase I immuno-oncology program.
Xenetic Biosciences, Inc. reported a smaller net loss for the quarter ended March 31, 2026 as royalty revenue increased. Royalty revenue rose to $806,923 from $593,261, while net loss narrowed to $456,382 from $903,141.
Operating expenses declined, with research and development and general and administrative costs both slightly lower than a year earlier. Cash was $7.3M and current liabilities about $1.0M, and the company believes existing resources can fund operations for at least twelve months, though additional capital will be needed longer term.
The company is conducting a formal strategic review, considering options including a sale, asset sale, or reverse merger that could leave counterparties’ investors holding a substantial majority of common stock. Xenetic continues to focus on advancing its DNase immuno-oncology technology and relies primarily on equity funding and royalties from its PolyXen license.
Xenetic Biosciences, Inc. filed an amendment to its annual report to add the Part III sections on directors, executive compensation, ownership and related-party transactions, and to update the cover-page share count to 2,291,056 common shares as of April 17, 2026. The filing details the board’s committee structure and independence, insider trading and related-party policies, and a single named executive officer, Interim CEO and CFO James Parslow. His 2025 total compensation was $536,027, including a $100,000 retention bonus and benefits, and he holds multiple option grants with exercise prices ranging from $3.88 to $548.40 per share. Pay-versus-performance tables show Compensation Actually Paid to the CEO moving broadly in line with total shareholder return and net losses, including a 2025 net loss of $2,680,860 and a total shareholder return value of $76.11 on a hypothetical $100 investment. The amendment also discloses 2025 audit and audit-related fees of $208,000, equity plan overhang of 115,622 options outstanding with 137,985 shares remaining available for issuance, and principal stockholders such as Renaissance Technologies LLC with 178,509 shares, or 7.8% of the common stock.